Biocon Q3 profit seen up 38% to Rs 142 cr on revenue, EBITDA

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

live

• bselive
• nselive

Volume

Todays L/H

More

×

Biopharmaceutical company Biocon's third quarter profit is likely to increase 38 percent year-on-year to Rs 142 crore and revenue may grow 15.5 percent to Rs 965.7 crore.

According to average of estimates of analysts polled by CNBC-TV18, operating profit (EBITDA - earnings before interest, tax, depreciation and amortisation) is seen rising 32.5 percent to Rs 240 crore and margin may expand 220 basis points to 24 percent compared with year-ago period.

Revenue growth is expected to pick up during the quarter while licensing income is likely to be subdued at around Rs 7 crore in Q3.

Analysts expect Syngene to lead growth with the contract research growth of 15-20 percent YoY. In Q2, Syngene growth was slower than expected at 14 percent against expectations of over 20 percent YoY.

They expect 12-14 percent in Bio-pharma sales. Within Bio-pharma, branded formulation sales may be impacted by discontinued oncology drug Abraxane sales.

Bio-pharma sales have regrouped under 3 segments - small molecules, branded formulations and biologics.